PR88231

SCHAFFHAUSEN, Switzerland, February 24, 2021, /PRNewswire=KYODO JBN/--

Occlutech, a privately-held company, announced today the completion of patient

enrolment in its pilot study to assess safety and efficacy of the novel Atrial

Flow Regulator (AFR) in heart failure (HF) patients (PRELIEVE trial).

PRELIEVE is a prospective, multicenter, open-label, non-randomized pilot study

that evaluates the results of AFR implantation in patients with either heart

failure with preserved ejection fraction (HFpEF) or heart failure with reduced

ejection fraction (HFrEF).

HF affects millions of people around the globe and has a big impact on

mortality and healthcare expenditure. Even with the best medical therapy, many

patients experience persistent symptoms and low quality of life as a result of

elevated left atrial pressure.

AFR is a minimally invasive cardiac implant that is designed to maintain a

permanent interatrial communication and allows controlled blood flow from

overloaded left atrium to the lower pressure right atrium.

"The completion of the enrolment is another important milestone for Occlutech

and we are excited to support this therapy option for heart failure patients

with our clinical activities." says Sabine Bois, CEO Occlutech Group.

Occlutech is one of the leading companies in its field, with several major

products including state-of-the-art PFO occluders, ASD occluders among others.

Occlutech has sales of congenital and structural heart products in over 80

countries and maintains manufacturing and R&D facilities in Jena, Germany and

Istanbul, Turkey. Occlutech has developed many novel products and technologies

to improve treatment of patients in these and related areas.

For additional information about the Company's products, the Occlutech AFR, or

to inquire about participation in our patient registries, please visit

Occlutech´s website at www.occlutech.com or contact us directly at

AFR@occlutech.com

The AFR is not approved in the United States.  Product availability is subject

to local regulatory clearance. The AFR is under clinical investigation for use

in patients with pulmonary arterial hypertension and use in these patients is

limited by applicable national laws.

Contact:

Sabine Bois

CEO Occlutech Group    

Mobile: +49 160 90792130                

Email: sabine.bois@occlutech.com

SOURCE: Occlutech International